Skip to content

Effectiveness of Radial Shockwave Therapy compared to Focused Shockwave Therapy for treating patellar tendinopathy

Effectiveness of Radial Shockwave Therapy compared to Focused Shockwave Therapy for treating patellar tendinopathy - TOPSHOCK-study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON34962
Enrollment
70
Registered
2010-03-12
Start date
2010-06-08
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patellar tendinopathy

Interventions

FSWT treatment and RSWT treatment will be given by an independent physical therapist. Shockwaves will be applied according to the guidelines of the International Society for Musculoskeletal Shockwav

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - History of knee pain in patellar tendon or its patellar or tibial insertion in connection with training and competition - Symptoms between three months (to exclude acute inflammatory tendon problems and de novo partial ruptures) and one year -received previous treatment, including eccentric training of the knee extensors/patellar tendon - Age 18-45 years old (to reduce the chance of other osteochondrotic diseases like Sinding-Larsen-Johanson, Osgood-Schlatter and osteoarthrosis) - Palpation tenderness to the corresponding painful area - VISA score

Exclusion criteria

Exclusion criteria: - acute knee or patellar tendon injuries - chronic joint diseases - signs or symptoms of other coexisting knee pathology - contraindications for SWT (pregnancy, malignancy, coagulopathy) - knee surgery or injection therapy with corticosteroids in the last preceding three months - daily use of drugs with a putative effect on patellar tendinopathy in the last year (e.g. non-steroid anti-inflammatory drugs, fluorchinolones) or actual use of anticoagulants

Design outcomes

Primary

MeasureTime frame
VISA-questionaire

Secondary

MeasureTime frame
VAS during: -activities of daily living -during sports -during a decline squat Overall treatment satisfaction

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)